Oncternal Therapeutics 10K/A 2022 Annual report (amended) | ONCT Filing

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	7th grade Good

New words: Aberdare, Adjunct, admitted, Agility, Ajuta, Alastin, Almozov, Aon, attending, Avalyn, Baxalta, Baxter, BBL, BDO, Becton, Behring, BIOCOM, biographical, biopharma, BioVenture, Bo, border, Cai, Calimmune, Caliper, CancerVax, Carmen, chairperson, chapter, Chase, Chen, child, Chinese, Cho, clawback, Codification, COO, CRISIMed, Cruz, CSL, custodian, DAARI, Dana, Dawei, Deloitte, denoted, depth, Dermata, designee, DeSimone, Dickinson, downstream, elapsed, Elpida, ensuing, entrepreneur, excise, Farber, Feldan, fell, fit, Florida, Fok, foregone, Francisco, fullest, Garcia, Ge, Gensia, Greifswald, Gu, Gunnar, headquartered, Heplisav, Histogen, HK, Houston, Huangpu, IDEC, Immusol, indemnify, informatiKon, Instruction, internist, Irvine, Jacksonville, Jiangnan, Jill, Jinzhu, Joyce, Jun, Kaufmann, Kinnate, Krishnan, Latham, Leavitt, Leonard, Li, Liang, Lineage, Lionel, Manson, Marburg, Mary, Mazanat, Meritage, Microbial, multinational, Neurana, nonprofit, Northeastern, Odonate, oncologist, oversaw, Pavlov, PDL, Pennsylvania, permissible, Petersburg, PhD, Phenomix, phrase, Plaza, PMV, predetermined, Princeton, prorated, Radford, Rady, Rajesh, recoupment, recovery, reinforce, representation, Rosette, Salim, Santa, seasoned, Serono, shell, Shen, Skincare, SkinMedica, SmithKline, Somaxon, Southern, spanned, SPHbio, spinoff, Sunvita, Taicang, Tang, TargeGen, Tekmira, tenure, tenured, Teva, Touche, UCB, unaffiliated, undertook, underwater, upstream, vehicle, Versatope, veteran, Viagene, Virology, welfare, Wharton, Wuhan, Yazji, Yongzhong, Yuansheng, Zerigo, Zhaoyang, Zhou, zilovertamab, zip, Zogenix, Zynerba

Removed: absence, acceptable, accepted, account, accounted, accrued, accuracy, achieved, achieving, acquirer, acquiring, adjusted, advance, advanced, adverse, adversely, affect, age, alternative, anemia, announced, anticipated, apply, approve, arise, asset, assurance, attract, attributable, audited, authority, authorization, avoid, balance, behalf, breach, calendar, central, certification, collaborating, combination, commerce, comprehensive, computed, computing, condition, confidential, consent, consisting, consulting, contingent, contract, contractual, controlled, converted, cost, coverage, cured, daily, damage, dated, deemed, deferred, delivery, depending, design, designated, developed, dilution, diminished, distributed, distribution, duly, effected, eliminated, encourage, enrollment, ensure, enter, entering, entity, evaluate, excluding, exclusive, executed, exhibit, exist, expect, expiration, expiring, extension, failing, failure, favorable, frequency, function, future, governed, governing, governmental, holder, identify, impair, important, inception, inconsistent, increase, increased, index, initially, injury, innovation, institutional, intellectual, involvement, largest, lead, lesser, letter, licensing, limitation, liquidation, long, lose, make, making, manage, manner, materially, matter, maximum, measured, notice, objective, obligation, obtain, occur, occurrence, office, offset, operation, pain, participant, participated, participating, participation, perform, physician, population, potential, preferred, preparation, presented, preventing, prohibit, promote, proprietary, purpose, quality, range, rate, ratio, receipt, recommendation, record, reduce, referred, refusal, register, regular, reimbursement, remain, replaced, requested, requirement, requiring, resale, reserved, retaining, return, reverse, safe, safety, satisfaction, satisfy, scope, seeking, selling, separately, shown, source, split, structure, subjective, subsequently, substantial, support, suspended, taxable, Tennessee, thereunto, timeframe, timely, timing, trade, transaction, treated, trial, ultimately, unauthorized, undersigned, understanding, undue, United, urinary, vary, weight, willfully


1.	I have reviewed this Form 10-K/A of Oncternal Therapeutics, Inc.; and


2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report.

Oncternal Therapeutics (ONCT) 10-K/A2022 FY Annual report (amended)

Content analysis